Skip to content

Corneal Cross-Linking Comparing Variables

Study of Safety and Efficacy of Photochemically Induced Collagen Cross-Linking at an Irradiance of 18 mW/cm2 as Constant or Pulsed Treatment in Eyes With Unstable Corneas Due to Keratoconus, Ectasia, or Post-Incisional Refractive Surgery

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02095730
Enrollment
500
Registered
2014-03-26
Start date
2014-05-31
Completion date
Unknown
Last updated
2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unstable Corneas

Keywords

crosslinking, cornea, keratoconus, ectasia, irradiance, riboflavin

Brief summary

The purpose of this study is to evaluate the Safety and Efficacy of Corneal Cross Linking in a Continuous Beam versus Pulsed Treatments across epithelium on and epithelium off surfaces.

Interventions

DRUGEpithelium-On Riboflavin

Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative

DRUGEpithelium-Off Riboflavin

Riboflavin 0.1% Phosphate Sodium solution

DEVICEUV Light - Continuous Beam

5 minutes of constant UV exposure to saturated cornea

DEVICEUV Pulsed Beam

5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes

Sponsors

Crowd Health Research, LTD
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Keratoconus: * 12 years of age or older * Having a clinical diagnosis of progressive keratoconus consistent with: 1. An increase of ≥ 1.00 D in the steepest keratometry value 2. An increase of ≥ 1.00 D in astigmatism manifest refraction 3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction * Presence of central or inferior steepening on the topography map. * Axial topography consistent with keratoconus * Steepest keratometry (Kmax) value ≥ 47.00 D * Signed written informed consent * Willingness and ability to comply with schedule for follow-up visits * Contact lens removal prior to evaluation and treatment Inclusion Criteria Post-Surgical Ectasia: * History of having undergone a keratorefractive procedure and: 1. Steepening by topography 2. Thinning of cornea 3. Shift in the position of thinnest portion of cornea 4. Change in refraction with increasing myopia 5. Development of myopic astigmatism 6. Development of irregular astigmatism 7. Loss of Best Spectacle Corrected Visual Acuity * At least two of the above criteria must be present. Inclusion Criteria Intacts: * Should the patient have undergone prior Intacs or other intra-corneal ring segment surgery for keratoconus or post-surgical ectasia at least 6 months prior, and is also experiencing at least two of the above ectasia symptoms, they can be included in the study. 1. These patients would have the choice of ring explant before Cross-Linking. 2. Cross-Linking may still be performed if the patient wishes to retain the rings. * Should a patient's situation due to factors such as significantly high myopia or astigmatism should warrant simultaneous placement of Intacs and cross-linking in the investigators opinion, then this option can be offered to the patient. Such interventions would be tracked as a different arm of the study. Inclusion Criteria RK/AK Fluctuation: * History of having undergone radial keratotomy (RK) and or astigmatic keratotomy (AK) surgery. * Expressing complaints about difficulties due to vision changing during the same day. * A difference in their Manifest Refraction (MRx) of greater than 0.75 D measured on the same day, at least 6 hours apart. * Intacs surgery will not be considered in patients with RK/AK.

Exclusion criteria

* Eyes classified as either normal, atypical normal, * Corneal pachymetry ≤ 350 microns at the thinnest point measured by Orbscan, Pentacam, or ultrasound in the eye to be treated * A history of chemical injury or delayed epithelial healing in the eye to be treated. * A known sensitivity to study medications * Patients with significant nystagmus or any other condition that would prevent a steady gaze during the treatment * Inability to cooperate with diagnostic tests. * Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing. * Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment. * Patients who are unable to remain comfortable and stable, and tolerate a lid speculum for the appointed period of time for the procedure.

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity2 yearsUncorrected visual acuity

Countries

United States

Contacts

Primary ContactTravis A Johnson, Bachelor's
tjohnson@libertylasereye.com571-234-5678
Backup ContactNancy A Tanchel, MD
ntanchel@libertylasereye.com571-234-5678

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026